共 947 条
[1]
Barnard ME(2015)Established breast cancer risk factors and risk of intrinsic tumor subtypes Biochim Biophys Acta 1856 73-85
[2]
Boeke CE(2009)Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 1160-1167
[3]
Tamimi RM(2015)Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine Am J Cancer Res 5 2330-2343
[4]
Parker JS(2012)Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis Breast Cancer Res Treat 134 957-967
[5]
Mullins M(2013)Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol 14 461-471
[6]
Cheang MC(2006)Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733-2743
[7]
Leung S(2017)Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial Lancet Oncol 18 732-742
[8]
Voduc D(2013)Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance Clin Breast Cancer 13 223-232
[9]
Vickery T(2013)Signatures of mutational processes in human cancer Nature 500 415-421
[10]
Murria R(2013)Cancer genome landscapes Science 339 1546-1558